Immunotherapy in the News

During 2015 the U.S. Food and Drug Administration (FDA) approved two immunotherapy drugs for the treatment of non-small cell lung cancer (NSCLC).

On March 4 the FDA expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous NSCLC with progression on or after platinum-based chemotherapy. Opdivo works by inhibiting the cellular pathway known as PD-1 protein on cells that blocks the body’s immune system from attacking cancerous cells.

Read the FDA release for Opdivo (nivolumab) here.

On October 2 the FDA granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) NSCLC whose disease has progressed after other treatments. Keytruda works by targeting the cellular pathway known as PD-1/PD-L1 (proteins found on the body’s immune cells and some cancer cells). By blocking this pathway, Keytruda may help the body’s immune system fight the cancer cells.

Read the FDA release for Keytruda (pembrolizumab) here.